GlassScriptPhysician profile
Susan U Moore
NPI 1770593212
$437,873.52
in general payments reported to CMS, 2019-2025
46 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97K · 2022: $75K · 2023: $122K · 2024: $103K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $204K · Honoraria: $21K · Travel and Lodging: $18K · Food and Beverage: $10K · Consulting Fee: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $204,462.50 |
| Honoraria | $20,720.00 |
| Travel and Lodging | $17,823.27 |
| Food and Beverage | $10,254.32 |
| Consulting Fee | $10,064.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323,660.34 | 2021-2025 | |
| Amgen INC. | $60,168.86 | 2021-2025 | Otezla, Otezla, Repatha |
| Axsome Therapeutics, INC. | $34,006.94 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $13,882.89 | 2021 | |
| Novo Nordisk INC | $869.54 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $674.33 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $544.44 | 2021-2024 | Trintellix |
| Corium, LLC | $422.59 | 2022-2025 | Azstarys |
| Lilly USA, LLC | $415.93 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Vanda Pharmaceuticals INC. | $355.56 | 2024-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $341.02 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.41 | 2023-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.33 | 2021-2024 | Xifaxan |
| Ironshore Pharmaceuticals INC. | $159.13 | 2022-2024 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $152.08 | 2021-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $150.25 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $144.23 | 2022-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $142.87 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $140.98 | 2021 | |
| Exact Sciences Corporation | $126.24 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $102.05 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $98.57 | 2025 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $97.09 | 2022 | |
| Phathom Pharmaceuticals, INC. | $94.64 | 2024 | Voquezna |
| Alkermes, INC. | $68.30 | 2022-2023 | Lybalvi |
| Esperion Therapeutics, INC. | $64.90 | 2023-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.61 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.98 | 2022-2025 | Cobenfy, Eliquis |
| Horizon Therapeutics Plc | $49.60 | 2021 | |
| Amarin Pharma, INC. | $45.46 | 2021-2022 | |
| Astellas Pharma US INC | $41.89 | 2023-2024 | Veozah |
| Eisai INC. | $41.83 | 2021 | |
| Sanofi Pasteur INC. | $33.45 | 2021 | |
| Merck Sharp & Dohme LLC | $32.93 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Insulet Corporation | $30.64 | 2025 | Omnipod |
| Tandem Diabetes Care, INC. | $27.59 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Currax Pharmaceuticals LLC | $26.61 | 2021 | |
| Globus Medical, INC. | $21.62 | 2025 | Senza |
| Otsuka America Pharmaceutical, INC. | $21.31 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.50 | 2022 | |
| Ardelyx, INC. | $15.40 | 2025 | Ibsrela |
| Lundbeck LLC | $15.13 | 2025 | Rexulti |
| Axonics, INC. | $14.95 | 2023 | Axonics |
| Paratek Pharmaceuticals, INC. | $14.78 | 2025 | Nuzyra, Xhance |
| Janssen Pharmaceuticals, INC | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.